Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Q1 Innovative Medicines (IM) sales grew across US and ex-US,
driven by our in-market growth drivers
IM sales USD 10.2bn (+4% cc)
US | Q1 2022 USD 3.7bn
+3% cc
Q1 2021
Q1 2022
1
GROWTH
Growth drivers +21% cc, 56% of IM sales
Ex-US | Q1 2022 USD 6.5bn
+5% CC 7
Q1 2022 USD 5.7bn
Q1 2021
Q1 2022
AimovigⓇ
PiqrayⓇ
56%
+21% vs. PY
MayzentⓇ
XiidraⓇ
LutatheraⓇ
48%
KymriahⓇ
KesimptaⓇ
KisqaliⓇ
Q1 2021
Q1 2022
All % growth relate to cc unless otherwise stated 1. Includes XolairⓇ, BeovuⓇ, Adakveo®, TabrectaⓇ, ScemblixⓇ, Enerzair®, AtecturaⓇ, Leqvio ®, Luxturna and Pluvicto®.
5 Investor Relations | Q1 2022 Results
llaris®
ZolgensmaⓇ
Jakavi®
Tafinlar+MekinistⓇ
PromactaⓇ
EntrestoⓇ
Cosentyx®
Other¹
✓ NOVARTIS | Reimagining MedicineView entire presentation